此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients

2026年11月10日 更新者:Linda Zhong、Nanyang Technological University

Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial

The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:

  1. Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
  2. Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.

Participants will:

  1. Receive acupuncture treatment twice per week for 6 weeks.
  2. Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
  3. Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

96

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Singapore、新加坡、S637551
        • Nanyang Technological University, School of Biological Sciences
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults aged 21 to 75 years at the time of consent;
  • Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
  • No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
  • GERD-Q score ≥8 (indicating active GERD symptoms);
  • Ability and willingness to provide written informed consent to participate.

Exclusion Criteria:

  • Structural or organic gastrointestinal disease, including but not limited to:

    1. gastrointestinal malignancy,
    2. eosinophilic esophagitis,
    3. esophageal stricture, varices, or infections,
    4. active peptic ulcer disease,
    5. gastric or duodenal tumors;
  • Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);

  • History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;

  • Use of prohibited medical treatment:

    1. acupuncture treatment on the abdomen and chest within past 1 month,
    2. concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
    3. antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
  • Presence of an implanted cardiac pacemaker;

  • History of hypersensitivity to acupuncture, or needle phobia;

  • Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;

  • Pregnant or breastfeeding;

  • Current participation in other clinical trials that could interfere with study outcomes.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Electroacupuncture (EA)

The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min.

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

假比较器:Sham-electroacupuncture (SEA)

The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention.

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
大体时间:From enrollment to the end of follow-up at 16 weeks

≥ 50% reduction in total GERD-Q score or normalization (<8)

From enrollment to the end of follow-up at 16 weeks
Gastrointestinal Symptom Rating scale (GSRS)
大体时间:From enrollment to the end of follow-up at 16 weeks

≥ 0.5 point decrease in mean GSRS Reflux domain value

From enrollment to the end of follow-up at 16 weeks

次要结果测量

结果测量
措施说明
大体时间
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
大体时间:From enrollment to the end of follow-up at 16 weeks

≥ 0.5 point improvement on the mean QOLRAD score

From enrollment to the end of follow-up at 16 weeks
Euro QoL (EQ-5D-5L)
大体时间:From enrollment to the end of follow-up at 16 weeks

change in index utility

From enrollment to the end of follow-up at 16 weeks
Hospital Anxiety and Depression Scale (HADS)
大体时间:From enrollment to the end of follow-up at 16 weeks

categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale

From enrollment to the end of follow-up at 16 weeks
Visceral Sensitivity Index (VSI)
大体时间:From enrollment to the end of follow-up at 16 weeks

≥ 15% reduction from baseline

From enrollment to the end of follow-up at 16 weeks
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
大体时间:From enrollment to the end of follow-up at 16 weeks

≥ 15% reduction from baseline

From enrollment to the end of follow-up at 16 weeks
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
大体时间:At baseline
At baseline
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
大体时间:From enrollment to the end of follow-up at 16 weeks

(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100%

From enrollment to the end of follow-up at 16 weeks
Bang's blinding index (BBI)
大体时间:End of first week and sixth week of intervention
End of first week and sixth week of intervention
James' blinding index (JBI)
大体时间:End of first week and sixth week of intervention
End of first week and sixth week of intervention
Patient's global impression of change (PGIC)
大体时间:From mid-treatment to the end of follow-up at 16 week
From mid-treatment to the end of follow-up at 16 week
Daily patient diary
大体时间:From enrollment to the end of follow-up at 16 weeks
From enrollment to the end of follow-up at 16 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Linda LD Zhong, PhD、Nanyang Technological University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2028年3月1日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

IPD sharing will be available upon request.

IPD 共享时间框架

Data will become available within 7 years after completion of the clinical trial.

IPD 共享访问标准

Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅